2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease
This guideline cites 3 of the 199 landmark trials in our Cardiology register.
- Issued by
- ACC/
AHA - Year
- 2025
- Source
- Gurvitz M, Krieger EV, et al. Circulation. 2026;153(8):e115–e251. Published online 18 December 2025.doi 10.1161/CIR.0000000000001402
The 2025 guideline replaces the 2018 ACHD document and, like the ESC 2020 guideline, is written for a population that has outlived its evidence: almost nothing here has been settled by a randomised trial. It keeps the American anatomic-physiologic (AP) classification — a two-axis system that grades lesion complexity and physiological stage separately, and has no ESC counterpart — and adds new measurement criteria for atrial septal defect closure, expanded guidance on pregnancy and delivery, and structured surveillance for Fontan-associated liver disease. The randomised exceptions are the pulmonary vasodilator trials in Eisenmenger syndrome and the Fontan circulation, plus the mechanical-valve anticoagulation question, grouped below.
Eisenmenger syndrome: advanced therapy2
- 2019MAESTROCardiology · PH / ACHD · Eisenmenger syndromeIn 226 patients with Eisenmenger syndrome in WHO functional class II–III, macitentan did not improve 6-minute walk distance compared with placebo.Read →
- 2006BREATHE-5Cardiology · PH / ACHD · Eisenmenger syndromeIn 54 patients with WHO functional class III Eisenmenger syndrome, bosentan lowered pulmonary vascular resistance and improved 6-minute walk distance without worsening systemic oxygen saturation compared with placebo.Read →
Fontan circulation1
- 2020FUELCardiology · PH / ACHD · Fontan circulationIn 400 adolescents with Fontan circulation, udenafil did not significantly improve peak oxygen consumption compared with placebo, although exercise performance at the ventilatory anaerobic threshold improved.2.8% vs -0.2%Read →
Cited landmark trials not yet in the register4
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2008BREATHE-5 open-label extension
Sustained bosentan benefit over 40 weeks in Eisenmenger syndrome.
- 2015TEMPO
Bosentan in the Fontan circulation — improved exercise capacity in a small randomised trial.
- 2020RIVER
Rivaroxaban versus warfarin after bioprosthetic mitral valve replacement — the boundary of DOAC use in valve disease.
- 2005CONCOR / Euro Heart Survey ACHD
The registries that define outcome expectations across congenital lesions.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.